专注于开发基于血液检测的癌症筛查技术的生物科技公司Grail公司（GRAL）的 Galleri 检测在一项大型英国国家医疗服务体系研究中未能达到主要终点，这对早期多癌检测血液检测来说是一个挫折；该公司报告称2025年售出了185000次检测。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.